Studies Address Muscle Loss Caused By GLP-1 Drugs

Follow Drugslib on

By Dennis Thompson HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on June 24, 2025.

via HealthDay

TUESDAY, June 24, 2025 — GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with fat.

Experts are now turning their attention toward helping GLP-1 patients maintain muscle while dropping fat, according to a pair of new studies presented at the American Diabetes Association’s annual meeting in Chicago.

An experimental muscle-preserving drug called bimagrumab helped people taking semaglutide (Ozempic/Wegovy) keep their muscle while losing weight, according to clinical trial results presented Monday.

In a separate study presented Sunday, researchers unveiled a potential test for tracking weight loss among GLP-1 patients.

“As we enter a new era of obesity treatments, it’s vital to focus not just on the amount of weight lost, but on preserving muscle mass and gaining the health benefits that result from treating obesity,” Dr. Samar Hafida, vice president of the Obesity Association — a division of the ADA – said in a news release.

The number of Americans taking GLP-1 drugs has increased nearly sixfold over the past five years, the ADA said in background notes.

Unfortunately, as much as 40% of the weight dropped on these drugs comes from loss of muscle mass rather than fat, the ADA says.

This muscle loss can have dramatic effects on a person’s health. Lean muscle mass stabilizes blood sugar, boosts immunity, protects bones and joints, and revs up metabolism, according to Northwell Health.

To try to prevent that loss, researchers combined bimagrumab with semaglutide in a clinical trial involving more than 500 people.

Bimagrumab is a lab-made antibody that blocks a protein called activin type II. This protein helps control how much muscle a person has. By blocking it, the drug helps the body build more muscle.

The drug initially was developed in the 2010s as a means of combatting muscle wasting diseases. Pharmaceutical firm Eli Lilly and Company — which makes Zepbound — is developing bimagrumab as a means of treating obesity.

Patients assigned bimagrumab in the clinical trial received IV infusions of the drug at weeks 4, 16, 28 and 40.

The combination of bimagrumab and semaglutide caused nearly 93% of people’s average weight loss to come from fat mass alone, results show.

By comparison, weight loss from fat alone amounted to just 72% for those taking just semaglutide, researchers found.

People also lost more body weight on the combination — a 22% decrease in weight compared with 11% for bimagrumab alone and 16% for semaglutide alone.

Researchers noted that in people who only took bimagrumab, 100% of weight loss came from fat melting away. These patients also had a more than 2% increase in their lean muscle mass.

“These insights indicate that is not only possible to achieve substantial fat loss, but also to preserve, or even enhance, lean mass in the process,” lead researcher Dr. Steven Heymsfield, a professor at Pennington Biomedical Research Center in Baton Rouge, La., said in a news release.

Researchers now are testing bimagrumab in combination with Zepbound to further evaluate the combo approach.

In the second study, researchers figured out a way to monitor muscle loss that occurs during GLP-1 treatment.

The team developed a biosensor to track phenylalanine, an amino acid produced when muscle breaks down or during the digestion of protein.

Phenylalanine levels in healthy people are 100 uM/L or higher following a high-protein meal, researchers said.

They designed their biosensor to detect phenylalanine levels up to 1500 uM/L, which might indicate muscle loss.

“GLP-1 medications have transformed the treatment of diabetes and obesity, but they can also increase the risk of muscle loss,” lead researcher Rebecca Gottlieb, vice president of Advanced Sensor Technologies at Biolinq, said in a news release.

“While patients are advised to consume more protein to preserve muscle, it’s often difficult to know if they’re getting enough,” Gottlieb said. “That is why solutions to bridge this gap by providing real-time feedback are more important than ever — especially for those on GLP-1 therapies, older adults, or anyone managing sarcopenia.”

Researchers next plan to conduct clinical trials to evaluate the sensor’s real-world performance.

Findings presented at medical meetings are considered preliminary until published in a peer-reviewed journal.

Sources

  • American Diabetes Association, news release, June 23, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-06-25 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords